Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2014

Open Access 01-12-2014 | Research article

Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histological assessment of specimens: a cohort study

Authors: Anjali Char, Nick S Hopkinson, David M Hansell, Andrew G Nicholson, Emily C Shaw, Samuel J Clark, Philip Sedgwick, Robert Wilson, Simon Jordan, Michael R Loebinger

Published in: BMC Pulmonary Medicine | Issue 1/2014

Login to get access

Abstract

Background

Patients with COPD are at risk of non-tuberculous mycobacterial infection (NTM). This study examined the histology of lung tissue from COPD patients following lung volume reduction with particular focus on evidence of mycobacterial infection.

Methods

Retrospective histological study of 142 consecutive lung volume reduction surgical specimens (126 separate patients) at Royal Brompton Hospital between 2000 – 2013, with prospectively collected preoperative data on exacerbation rate, lung function and body mass index.

Results

92% of patients had at least one other histological diagnosis in addition to emphysema. 10% of specimens had histological evidence of mycobacterial infection, one with co-existent aspergilloma. Mycobacteria were only identified in those patients with granulomas that were necrotising. These patients had higher exacerbation rates, lower TLCO and FEV1.

Conclusion

A proportion of severe COPD patients will have evidence of mycobacterial infection despite lack of clinical and radiological suspicion. This may have implications for long-term management of these patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sexton P, Harrison AC: Susceptibilty to nontuberculosis mycobacterial lung disease. Eur Respir J. 2008, 31: 1322-1333.CrossRefPubMed Sexton P, Harrison AC: Susceptibilty to nontuberculosis mycobacterial lung disease. Eur Respir J. 2008, 31: 1322-1333.CrossRefPubMed
2.
go back to reference Griffith DE, Aksamit T, Brown-Elliot BA, Cantanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, Fordham von Reyn C, Wallace RJ, Winthro K: An official ATS/IDSA statement: diagnosis, treatement and prevention of nontuberculosis mycobacterial diseases. Am J Respir Crit Med. 2007, 175: 162-166.CrossRef Griffith DE, Aksamit T, Brown-Elliot BA, Cantanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, Fordham von Reyn C, Wallace RJ, Winthro K: An official ATS/IDSA statement: diagnosis, treatement and prevention of nontuberculosis mycobacterial diseases. Am J Respir Crit Med. 2007, 175: 162-166.CrossRef
3.
go back to reference Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society: Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax. 2000, 55: 210-218.CrossRef Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society: Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax. 2000, 55: 210-218.CrossRef
4.
5.
go back to reference Cowman S, Wilson R, Loebinger MR: Opportunistic mycobacterial diseases. Medicine. 2012, 40 (6): 346-348.CrossRef Cowman S, Wilson R, Loebinger MR: Opportunistic mycobacterial diseases. Medicine. 2012, 40 (6): 346-348.CrossRef
6.
go back to reference Marusic A, Katalinic-Jankovic V, Popovic-Grle S, Jankovic M, Mazuranic I, Puljic I, Sertic Milic H: Mycobacterium xenopi pulmonary disease- epidemiology and clinical features in non-immunocompromised patients. J Infect. 2009, 58: 108-112.CrossRefPubMed Marusic A, Katalinic-Jankovic V, Popovic-Grle S, Jankovic M, Mazuranic I, Puljic I, Sertic Milic H: Mycobacterium xenopi pulmonary disease- epidemiology and clinical features in non-immunocompromised patients. J Infect. 2009, 58: 108-112.CrossRefPubMed
7.
go back to reference Goldstein RS, Todd TRJ, Guyatt G, Keshavjee S, Dolmage TE, van Rooy S, Krip B, Maltais F, LeBlanc P, Pakhale S, Waddell TK: Influence of lung volume reduction surgery (LVRS) on health related quality of life in patients with chronic obstructive pulmonary disease. Thorax. 2003, 58: 405-410.CrossRefPubMedPubMedCentral Goldstein RS, Todd TRJ, Guyatt G, Keshavjee S, Dolmage TE, van Rooy S, Krip B, Maltais F, LeBlanc P, Pakhale S, Waddell TK: Influence of lung volume reduction surgery (LVRS) on health related quality of life in patients with chronic obstructive pulmonary disease. Thorax. 2003, 58: 405-410.CrossRefPubMedPubMedCentral
8.
go back to reference Keller CA, Naunheim KS, Osterloh J, Espiritu J, McDonald JW, Ramos RR: Histopathologic diagnosis made in lung tissue resected from patients with severe emphysema undergoing lung volume reduction surgery. Chest. 1997, 111 (4): 941-947.CrossRefPubMed Keller CA, Naunheim KS, Osterloh J, Espiritu J, McDonald JW, Ramos RR: Histopathologic diagnosis made in lung tissue resected from patients with severe emphysema undergoing lung volume reduction surgery. Chest. 1997, 111 (4): 941-947.CrossRefPubMed
9.
go back to reference Criner GJ, Cordova F, Sternberg AL, Martinez FJ: The National Emphysema Treatment Trial (NETT): part I: lessons learned about emphysema. Am J Respir Crit Care Med. 2011, 184 (7): 763-770.CrossRefPubMed Criner GJ, Cordova F, Sternberg AL, Martinez FJ: The National Emphysema Treatment Trial (NETT): part I: lessons learned about emphysema. Am J Respir Crit Care Med. 2011, 184 (7): 763-770.CrossRefPubMed
10.
go back to reference Criner GJ, Cordova F, Sternberg AL, Martinez FJ: The National Emphysema Treatment Trial (NETT) part II: lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med. 2011, 184 (8): 881-893.CrossRefPubMedPubMedCentral Criner GJ, Cordova F, Sternberg AL, Martinez FJ: The National Emphysema Treatment Trial (NETT) part II: lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med. 2011, 184 (8): 881-893.CrossRefPubMedPubMedCentral
11.
go back to reference Clark SJ, Zoumot Z, Bamsey O, Polkey MI, Dusmet M, Lim E, Jordan S, Hopkinson NS: Surgical approaches for lung volume reduction surgery in emphysema. Clin Med. 2014, In pres Clark SJ, Zoumot Z, Bamsey O, Polkey MI, Dusmet M, Lim E, Jordan S, Hopkinson NS: Surgical approaches for lung volume reduction surgery in emphysema. Clin Med. 2014, In pres
12.
go back to reference Duarte IG, Gal AA, Mansour KA, Lee RB, Miller JI: Pathologic findings in lung volume reduction surgery. Chest. 1998, 113 (3): 661-664.CrossRef Duarte IG, Gal AA, Mansour KA, Lee RB, Miller JI: Pathologic findings in lung volume reduction surgery. Chest. 1998, 113 (3): 661-664.CrossRef
13.
go back to reference Hazelrigg SR, Boley TM, Weber D, Magee MJ, Naunheim KS: Incidence of lung nodules found in patients undergoing lung volume reduction. Ann Thorac Surg. 1997, 64 (2): 303-306.CrossRefPubMed Hazelrigg SR, Boley TM, Weber D, Magee MJ, Naunheim KS: Incidence of lung nodules found in patients undergoing lung volume reduction. Ann Thorac Surg. 1997, 64 (2): 303-306.CrossRefPubMed
14.
go back to reference Andrejak C, Nielsen R, Thomson R, Dahaut P, Sorensen HT, Thomsen RW: Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculosis mycobacteriosis. Thorax. 2013, 68 (3): 256-262.CrossRefPubMed Andrejak C, Nielsen R, Thomson R, Dahaut P, Sorensen HT, Thomsen RW: Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculosis mycobacteriosis. Thorax. 2013, 68 (3): 256-262.CrossRefPubMed
15.
go back to reference Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K: Pulmonary nontuberculosis mycobacterial disease prevalence and clinical features. Am J Respir Crit Med. 2010, 182: 977-982.CrossRef Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K: Pulmonary nontuberculosis mycobacterial disease prevalence and clinical features. Am J Respir Crit Med. 2010, 182: 977-982.CrossRef
16.
go back to reference Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG: Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011, 365: 689-698.CrossRefPubMedPubMedCentral Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG: Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011, 365: 689-698.CrossRefPubMedPubMedCentral
17.
go back to reference Pedrazzoli D, Anderson L, Lalor M, Davidson J, Abubakar I, Thomas L: Tuberculosis in the UK: 2013 Report. Public Health England. 2013, 1-46. Pedrazzoli D, Anderson L, Lalor M, Davidson J, Abubakar I, Thomas L: Tuberculosis in the UK: 2013 Report. Public Health England. 2013, 1-46.
Metadata
Title
Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histological assessment of specimens: a cohort study
Authors
Anjali Char
Nick S Hopkinson
David M Hansell
Andrew G Nicholson
Emily C Shaw
Samuel J Clark
Philip Sedgwick
Robert Wilson
Simon Jordan
Michael R Loebinger
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2014
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-14-124

Other articles of this Issue 1/2014

BMC Pulmonary Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.